Among these gene polymorphisms, CTLA4 rs231775, HLA polymorphisms (DRB1*03, DQA1*05, and DQB1*02), CD40 polymorphisms (rs745307, rs11569309, and rs3765457), PTPN22 polymorphism (rs2476601), T393C SNP of GNAS1 and Tg E33SNP were observed to be associated with the high-recurrence risk in GD patients after ATD withdrawal (8–13). The gene discussed is GNAS; the disease is Jeune syndrome.